Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (241) Apply Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Summaries of opinion (9) Apply Summaries of opinion filter Orphan designations (49) Apply Orphan designations filter Referrals (4) Apply Referrals filter Direct healthcare professional communication (17) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (6) Apply Yes filter

Authorisation status

Authorised (152) Apply Authorised filter Refused (2) Apply Refused filter Withdrawn (27) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (4) Apply Initial authorisation filter Post-authorisation (1) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (8) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (43) Apply PM: decision on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (13) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (13) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Conditional approval Remove Conditional approval filter Additional monitoring (567) Apply Additional monitoring filter Exceptional circumstances (54) Apply Exceptional circumstances filter Generic (330) Apply Generic filter Orphan medicine (277) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

250 results

Remove all filtersRemove all filters

Medicine Withdrawn applications Remove Withdrawn applications filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter

Medicine type Biosimilar Remove Biosimilar filter Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter

Sort by

List item

Human medicine European public assessment report (EPAR): Blitzima

rituximab, Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 13/07/2017, , Revision: 15, Authorised, Last updated: 13/07/2022
List item

Human medicine European public assessment report (EPAR): Darzalex

Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016, , , Revision: 19, Authorised, Last updated: 11/07/2022
List item

Human medicine European public assessment report (EPAR): Dovprela (previously Pretomanid FGK)

Pretomanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 31/07/2020, , , , Revision: 6, Authorised, Last updated: 08/07/2022
List item

Human medicine European public assessment report (EPAR): Zynteglo

Autologous CD34+ cell enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene, beta-Thalassemia
Date of authorisation: 29/05/2019, , , , , , Revision: 5, Withdrawn, Last updated: 08/07/2022
List item

Human medicine European public assessment report (EPAR): Harvoni

ledipasvir, Sofosbuvir, Hepatitis C, Chronic
Date of authorisation: 17/11/2014, , Revision: 25, Authorised, Last updated: 06/07/2022
List item

Human medicine European public assessment report (EPAR): Sovaldi

Sofosbuvir, Hepatitis C, Chronic
Date of authorisation: 16/01/2014, , Revision: 25, Authorised, Last updated: 06/07/2022
List item

Human medicine European public assessment report (EPAR): Paxlovid

(1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide [PF-07321332], ritonavir, COVID-19 virus infection
Date of authorisation: 28/01/2022, , Revision: 2, Authorised, Last updated: 06/07/2022
List item

Human medicine European public assessment report (EPAR): Epclusa

Sofosbuvir, velpatasvir, Hepatitis C, Chronic
Date of authorisation: 06/07/2016, , Revision: 18, Authorised, Last updated: 06/07/2022
List item

Human medicine European public assessment report (EPAR): Alymsys

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021, , , Revision: 3, Authorised, Last updated: 06/07/2022
List item

Human medicine European public assessment report (EPAR): Oyavas

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021, , , Revision: 3, Authorised, Last updated: 05/07/2022
List item

Human medicine European public assessment report (EPAR): Inhixa

enoxaparin sodium, Venous Thromboembolism
Date of authorisation: 15/09/2016, , Revision: 21, Authorised, Last updated: 01/07/2022
List item

Human medicine European public assessment report (EPAR): Caprelsa

Vandetanib, Thyroid Neoplasms
Date of authorisation: 16/02/2012, , , Revision: 22, Authorised, Last updated: 30/06/2022
List item

Human medicine European public assessment report (EPAR): Ocaliva

Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016, , , , Revision: 13, Authorised, Last updated: 30/06/2022
List item

Human medicine European public assessment report (EPAR): Bemfola

follitropin alfa, Anovulation
Date of authorisation: 26/03/2014, , Revision: 9, Authorised, Last updated: 28/06/2022
List item

Human medicine European public assessment report (EPAR): Rozlytrek

Entrectinib, Cancer; Carcinoma, Non-Small-Cell Lung
Date of authorisation: 31/07/2020, , , Revision: 4, Authorised, Last updated: 27/06/2022
List item

Human medicine European public assessment report (EPAR): Accofil

filgrastim, Neutropenia
Date of authorisation: 17/09/2014, , Revision: 13, Authorised, Last updated: 24/06/2022
List item

Human medicine European public assessment report (EPAR): Lunsumio

mosunetuzumab, Lymphoma, Follicular
Date of authorisation: 03/06/2022, , , , Authorised, Last updated: 23/06/2022
List item

Human medicine European public assessment report (EPAR): Kanuma

sebelipase alfa, Lipid Metabolism, Inborn Errors
Date of authorisation: 28/08/2015, , , , Revision: 8, Authorised, Last updated: 21/06/2022
List item

Human medicine European public assessment report (EPAR): Maviret

glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, , Revision: 16, Authorised, Last updated: 20/06/2022
List item

Human medicine European public assessment report (EPAR): Carvykti

ciltacabtagene autoleucel, Multiple Myeloma
Date of authorisation: 25/05/2022, , , , Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Ondexxya

andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019, , , Revision: 12, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Kisplyx

lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016, , Revision: 17, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Evrysdi

Risdiplam, Muscular Atrophy, Spinal
Date of authorisation: 26/03/2021, , , Revision: 2, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Ninlaro

ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016, , , , Revision: 14, Authorised, Last updated: 17/06/2022
List item

Human medicine European public assessment report (EPAR): Kyprolis

carfilzomib, Multiple Myeloma
Date of authorisation: 19/11/2015, , , Revision: 20, Authorised, Last updated: 15/06/2022